Delcath Systems (NASDAQ:DCTH) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a sell rating in a research report released on Monday.

Other equities analysts have also issued research reports about the stock. Stephens reiterated an overweight rating and issued a $25.00 price objective on shares of Delcath Systems in a report on Tuesday, August 6th. Craig Hallum started coverage on Delcath Systems in a research note on Friday, June 28th. They issued a buy rating and a $18.00 price target on the stock. Finally, HC Wainwright restated a buy rating and set a $22.00 price objective on shares of Delcath Systems in a research note on Tuesday, August 6th.

Delcath Systems Stock Performance

DCTH stock opened at $9.96 on Monday. The firm has a market cap of $276.75 million, a P/E ratio of -3.76 and a beta of 0.78. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $11.74. The stock has a 50-day simple moving average of $8.63 and a 200-day simple moving average of $6.83.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.12). Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. The firm had revenue of $7.77 million during the quarter, compared to analyst estimates of $5.00 million. During the same period last year, the business earned ($0.58) EPS. On average, equities research analysts predict that Delcath Systems will post -1.33 EPS for the current year.

Institutional Investors Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently modified their holdings of DCTH. Levin Capital Strategies L.P. grew its position in shares of Delcath Systems by 12.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after acquiring an additional 5,969 shares in the last quarter. Marshall Wace LLP lifted its stake in Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after purchasing an additional 6,066 shares during the last quarter. AIGH Capital Management LLC boosted its holdings in Delcath Systems by 1.7% in the second quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock worth $20,086,000 after purchasing an additional 40,064 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Delcath Systems during the second quarter valued at $370,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Delcath Systems during the second quarter worth $694,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.